All In Biotech

NDA 022268 · Novartis

Coartem

Artemether, Lumefantrine · Oral · Antimalarial

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Aug 5, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Apr 7, 2009

Approved uses

1

Original approval plus efficacy supplements

Registered trials

223

54 Phase 3, 8 recruiting

FAERS reports

198

174 serious, 23 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 26, 2026.

Coartem Tablets are indicated for treatment of acute, uncomplicated malaria infections due to Plasmodium falciparum (P. falciparum) in patients 2 months of age and older with a bodyweight of 5 kg and above. Coartem Tablets have been shown to be effective in geographical regions where resistance to chloroquine has been reported [see Clinical Studies (14.1)] . Limitations of Use : Coartem Tablets are not approved for patients with severe or complicated P. falciparum malaria. Coartem Tablets are not approved for the prevention of malaria. Coartem Tablets are a combination of artemether and lumefantrine, both antimalarials, indicated for treatment of acute, uncomplicated malaria infections due to Plasmodium falciparum (P. falciparum) in patients 2 months of age and older with a bodyweight of 5 kg and above. ( 1 ) Coartem Tablets have been shown to be effective in geographical regions where resistance to chloroquine has been reported. ( 1 ) Limitations of Use: ( 1 ) Coartem Tablets are not approved for patients with severe or complicated P. falciparum malaria . Coartem Tablets are not approved for the prevention of malaria.

Mechanism: Coartem Tablets, a fixed dose combination of artemether and lumefantrine in the ratio of 1:6, is an antimalarial agent [see Microbiology (12.4)] .

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 7, 2009 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
  • COARTEM · ARTEMETHER 20MG; LUMEFANTRINE 120MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Artemether" as an intervention, any sponsor and status, largest first.

All 223 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pyrexia22
  • vomiting18
  • dyspnoea17
  • asthenia16
  • malaise13
  • malaria13
  • drug ineffective12
  • maternal exposure during pregnancy11
  • headache10
  • anaemia9
  • dizziness9
  • pain9

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20062
20099
201019
201112
201211
20136
201412
201519
20168
201718
201818
201912
202013
202110
20227
20236
20243
20257
20266

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Coartem (Artemether/Lumefantrine)

2024 spending

$83K

Beneficiaries

146

324 claims

Per beneficiary

$569

$5.59 per unit

View as table
YearSpending
2020$75,008
2021$71,376
2022$65,905
2023$95,092
2024$83,102

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 650 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.